Transcode Therapeutics (RNAZ) EBT (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported EBT for 7 consecutive years, with -$6.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 57.84% year-over-year to -$6.7 million; the trailing twelve-month figure through Jun 2026 stood at -$44.8 million (down 89.65% YoY), and the FY2025 full-year result was -$34.4 million, down 105.52% from the prior year.
• EBT advanced to -$6.7 million in Q2 2026 per RNAZ's latest filing, from -$17.6 million in the prior quarter.
• Across five years, EBT topped out at -$2.2 million in Q3 2024 and bottomed at -$17.6 million in Q1 2026.
• Historically, EBT has averaged -$6.4 million across 5 years, with a median of -$5.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: EBT sank 592.33% in 2022, then soared 59.15% in 2024.
• Over 5 years, EBT stood at -$5.5 million in 2022, then climbed by 24.99% to -$4.1 million in 2023, then dropped by 23.8% to -$5.1 million in 2024, then tumbled by 213.08% to -$15.9 million in 2025, then jumped by 57.68% to -$6.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$6.7 million, -$17.6 million, and -$15.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.